Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patrick Guinan

Showing results (11-20 of 36) with videos related to

Pageof 4
Sort By:
Medical Oncology (Northwood, London, England)|June 18, 2009
Treatment of prostate and breast tumors employing mono- and bi-specific antisense oligonucleotides targeting apoptosis inhibitory proteins clusterin and bcl-2Marvin Rubenstein, Paulus Tsui, Patrick Guinan
Medical Oncology (Northwood, London, England)|August 8, 2008
Multigene targeting of signal transduction pathways for the treatment of breast and prostate tumors: comparison between combination therapies employing bispecific oligonucleotides with either Rapamycin or PaclitaxelMarvin Rubenstein, Paulus Tsui, Patrick Guinan
Journal of Biomedicine & Biotechnology|September 30, 2005
Correlation between PSMA and VEGF expression as markers for LNCaP tumor angiogenesisPaulus Tsui, Marvin Rubenstein, Patrick Guinan
Medical Oncology (Northwood, London, England)|December 8, 2004
Synergistic effects of combination therapy employing antisense oligonucleotides with traditional chemotherapeutics in the PC-3 prostate cancer modelPaulus Tsui, Marvin Rubenstein, Patrick Guinan
Drug Delivery|June 19, 2004
Two constructed antibody-derived delivery vehicles for targeting oligodeoxynucleotides to prostate tumors expressing prostate specific antigenYelena Mirochnik, Marvin Rubenstein, Patrick Guinan
In Vivo (Athens, Greece)|February 21, 2013
Review: description of the developmental patterns of epithelial cells and cancers originating from them will provide many sites for therapyKen M Anderson, Patrick Guinan, Marvin Rubenstein
In Vivo (Athens, Greece)|July 15, 2011
Effects of BCL-2 suppression by antisense oligonucleotides on additional regulators of apoptosis compensatory change in non-targeted protein expressionMarvin Rubenstein, Courtney M P Hollowell, Patrick Guinan
Therapeutic Advances in Urology|August 27, 2011
In LNCaP cells enhanced expression of the androgen receptor compensates for Bcl-2 suppression by antisense oligonucleotidesMarvin Rubenstein, Courtney M P Hollowell, Patrick Guinan
Medical Oncology (Northwood, London, England)|May 17, 2011
Differentiated prostatic antigen expression in LNCaP cells following treatment with bispecific antisense oligonucleotides directed against BCL-2 and EGFRMarvin Rubenstein, Courtney M P Hollowell, Patrick Guinan
Therapeutic Advances in Urology|December 14, 2011
In LNCaP cells enhanced expression of both androgen receptor and costimulatory protein p300 compensate for antisense oligonucleotide suppression of bcl-2Marvin Rubenstein, Courtney M P Hollowell, Patrick Guinan
Pageof 4

Showing results (11-20 of 36) with videos related to

Sort By:
Pageof 4
Medical Oncology (Northwood, London, England)|June 18, 2009
Treatment of prostate and breast tumors employing mono- and bi-specific antisense oligonucleotides targeting apoptosis inhibitory proteins clusterin and bcl-2Marvin Rubenstein, Paulus Tsui, Patrick Guinan
Medical Oncology (Northwood, London, England)|August 8, 2008
Multigene targeting of signal transduction pathways for the treatment of breast and prostate tumors: comparison between combination therapies employing bispecific oligonucleotides with either Rapamycin or PaclitaxelMarvin Rubenstein, Paulus Tsui, Patrick Guinan
Journal of Biomedicine & Biotechnology|September 30, 2005
Correlation between PSMA and VEGF expression as markers for LNCaP tumor angiogenesisPaulus Tsui, Marvin Rubenstein, Patrick Guinan
Medical Oncology (Northwood, London, England)|December 8, 2004
Synergistic effects of combination therapy employing antisense oligonucleotides with traditional chemotherapeutics in the PC-3 prostate cancer modelPaulus Tsui, Marvin Rubenstein, Patrick Guinan
Drug Delivery|June 19, 2004
Two constructed antibody-derived delivery vehicles for targeting oligodeoxynucleotides to prostate tumors expressing prostate specific antigenYelena Mirochnik, Marvin Rubenstein, Patrick Guinan
In Vivo (Athens, Greece)|February 21, 2013
Review: description of the developmental patterns of epithelial cells and cancers originating from them will provide many sites for therapyKen M Anderson, Patrick Guinan, Marvin Rubenstein
In Vivo (Athens, Greece)|July 15, 2011
Effects of BCL-2 suppression by antisense oligonucleotides on additional regulators of apoptosis compensatory change in non-targeted protein expressionMarvin Rubenstein, Courtney M P Hollowell, Patrick Guinan
Therapeutic Advances in Urology|August 27, 2011
In LNCaP cells enhanced expression of the androgen receptor compensates for Bcl-2 suppression by antisense oligonucleotidesMarvin Rubenstein, Courtney M P Hollowell, Patrick Guinan
Medical Oncology (Northwood, London, England)|May 17, 2011
Differentiated prostatic antigen expression in LNCaP cells following treatment with bispecific antisense oligonucleotides directed against BCL-2 and EGFRMarvin Rubenstein, Courtney M P Hollowell, Patrick Guinan
Therapeutic Advances in Urology|December 14, 2011
In LNCaP cells enhanced expression of both androgen receptor and costimulatory protein p300 compensate for antisense oligonucleotide suppression of bcl-2Marvin Rubenstein, Courtney M P Hollowell, Patrick Guinan
Pageof 4